Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells
The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.
Dr. Cowan on Efficacy and Safety of BCMA CAR T-Cells in Multiple Myeloma
Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512